Mounjaro on the NHS in 2026: who qualifies now, and who is next in 2027
NHS England is rolling out tirzepatide in phases under NICE TA1026. Who qualifies from June 2026, who is expected from March 2027, and how to prepare.
If you live in England, you can get tirzepatide (Mounjaro) for weight management on the NHS only if you fall into one of the groups NHS England is currently offering it to. Since around June 2026 that has included adults with a BMI of 35 to 39.9 and four or more of the listed weight-related conditions, on top of the first group with a BMI of 40 or more. The next group, with a BMI of 40 or more and three conditions, is expected from around March 2027.
That is the short answer. The longer one is worth knowing, because the phased rollout means two people with the same BMI can get very different answers from their GP depending on their other health conditions and the date they ask.
Why the NHS is doing it in phases
NICE's technology appraisal TA1026 recommends tirzepatide, alongside a reduced-calorie diet and more physical activity, for adults with an initial BMI of at least 35 and at least one weight-related condition. On paper, that is a large group. In practice, NICE agreed a funding variation so that the NHS in England could introduce the medicine gradually over roughly three years instead of all at once. NHS England published interim commissioning guidance setting out who comes first.
NICE was clear that it could not recommend tirzepatide for the wider group the manufacturer proposed (BMI of 30 or more with one condition), because the cost-effectiveness estimates for that group were above what NICE considers acceptable for the NHS.
The phases at a glance
The table below is based on NICE's plain-English summary of the NHS England plan. Dates are approximate, because local services start at different speeds.
| From around | BMI | Weight-related conditions |
|---|---|---|
| Already eligible (first group) | 40 or more | 4 or more |
| June 2026 | 35 to 39.9 | 4 or more |
| March 2027 | 40 or more | 3 |
For people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, NICE says the qualifying BMI is 2.5 lower (for example 37.5 instead of 40), because weight-related health risks start at lower BMIs in these groups.
Which conditions count?
NICE's summary of the NHS England plan lists five weight-related conditions that are counted:
- high blood pressure
- dyslipidaemia (abnormal blood fats)
- obstructive sleep apnoea
- cardiovascular disease, for example heart disease
- type 2 diabetes
Other conditions linked to weight, such as joint pain, do not count towards these phases, however real they are. The conditions also need to be diagnosed and recorded in your notes; a suspicion of sleep apnoea, for example, is not the same as a confirmed diagnosis. If you think a condition is missing from your record, ask the practice how it can be assessed.
What happens at the GP surgery
NICE says tirzepatide can be used in primary care or in specialist weight management services. In a GP setting you can expect:
- A check of your record. Your BMI and diagnoses need to be documented. If a condition was diagnosed privately or abroad, bring paperwork.
- Wraparound support. NICE expects the medicine to be used alongside diet and activity support. The availability of that support varies by area.
- A plan for review. NICE says that if less than 5% of your initial weight has been lost after six months on the highest tolerated dose, the decision to continue should be revisited with you.
- Safety information. Expect to hear about common stomach side effects, contraception and what to do if you get severe tummy pain.
If you are not in a current phase, your GP cannot simply bring you forward. You can ask to be told when your group opens and what other support is available in the meantime.
Already on Mounjaro privately?
NICE's guidance says it is not intended to affect treatment that was started in the NHS before publication. For people paying privately, nothing in TA1026 moves you automatically onto an NHS prescription. If you meet the criteria of a current phase, your GP will still assess you in the usual way. Mention any private treatment, including your current dose and how long you have been on it, so the clinician has the full picture.
Bring a simple record to that appointment: start date, dose history, weights and any side effects. A diary such as GLP-1 Diary can turn that into a short PDF, but a page of handwritten notes works just as well. What matters is that the information is accurate and dated.
Safety updates that came with the rollout
The rollout happened alongside several MHRA safety communications, and your GP or pharmacist may raise them:
- Pancreatitis. On 29 January 2026 the MHRA updated product information on the small risk of severe acute pancreatitis. Severe, persistent stomach pain that may spread to the back, with or without nausea and vomiting, needs urgent medical attention.
- Contraception. Tirzepatide may reduce the effectiveness of the pill in people who are overweight. The NHS medicines page advises a barrier method for four weeks after starting and after each dose increase. We explain this in detail in GLP-1 medicines, contraception and pregnancy.
- Genuine supply only. The MHRA reminds patients that a legitimate pharmacy and a prescription are the only way to be sure the medicine is genuine.
Questions to take to your appointment
- Which phase am I in, and when does my group become eligible if I am not in one yet?
- Which of my conditions are counted under the NHS England list?
- Who will review me at six months, and what happens if the result is below 5%?
- Who do I contact about side effects between appointments: the practice, the pharmacist or NHS 111?
- How will my prescription be issued, and how many pens will I receive at a time?
Scotland, Wales and Northern Ireland
TA1026 applies to England. The devolved nations make their own arrangements for new medicines, so the phases and dates above do not automatically apply. If you live outside England, ask your GP practice or health board what is currently offered.
The bottom line
The NHS route to Mounjaro is real, but it is staged and tightly defined. Check which group you are in, get your conditions recorded, and keep good notes of your own progress. If you are already on treatment, read our guide to rotating injection sites and keep your prescriber informed about side effects. Your GP, practice nurse or pharmacist is the right person for any question about whether the medicine and the dose are right for you.
Injection sites, weight, side effects and a clear report for your doctor or nurse.
Download on the App StoreFrequently asked questions
Can my GP prescribe Mounjaro for weight loss on the NHS?
Yes, if you fall into a group that is currently being offered it. NICE says tirzepatide can be used in primary care or in specialist weight management services, but NHS England is introducing it in phases, so eligibility depends on your BMI and how many of the listed weight-related conditions you have.
Who becomes eligible from March 2027?
According to NICE's summary of the NHS England plan, people with three of the listed weight-related conditions and a BMI of 40 or more may become eligible from around March 2027. The BMI threshold is 2.5 lower for people from some ethnic backgrounds.
What happens if I lose less than 5% in six months?
NICE says that if less than 5% of initial weight has been lost after six months on the highest tolerated dose, the prescriber should decide with you whether to continue, weighing benefits and risks.